CN Patent

CN114729376A — 用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法

Assigned to Omega Therapeutics Inc · Expires 2022-07-08 · 4y expired

What this patent protects

本发明提供用于通过靶向HNF4α表达控制区来调节肝细胞核因子4α(HNF4α)基因的表达(例如增加或降低的表达)的试剂和组合物及其用于治疗HNF4α相关病症(例如肝硬化)的使用方法。

USPTO Abstract

本发明提供用于通过靶向HNF4α表达控制区来调节肝细胞核因子4α(HNF4α)基因的表达(例如增加或降低的表达)的试剂和组合物及其用于治疗HNF4α相关病症(例如肝硬化)的使用方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN114729376A
Jurisdiction
CN
Classification
—
Expires
2022-07-08
Drug substance claim
No
Drug product claim
No
Assignee
Omega Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.